Background and current knowledge of Chlamydia pneumoniae and atherosclerosis

Journal of Infectious Diseases

Volumn 181, Issue 6 SUPPL. 3, 2000, Pages

  Grayston, J Thomas ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC THERAPY; ATHEROMA; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; HUMAN; IMMUNOPATHOLOGY; MYOCARDITIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SEROEPIDEMIOLOGY;

EID: 0034097981     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315596     Document Type: Conference Paper

References (74)

1. 1. Grayston JT, Wang SP. History of Chlamydia pneumoniae (TWAR). In: Allegra L, Blasi F, eds. Chlamydia pneumoniae: the lung and heart. Milan: Springer, 1999:1-8.
2. 2. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986;315:161-8.
3. 3. Wang SP, Grayston JT. Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am J Ophthalmol 1970;70:367-74.
4. 4. Grayston JT. Chlamydia pneumoniae, strain TWAR pneumonia. Annu Rev Med 1992;43:317-23.
5. 5. Aldous MB, Grayston JT, Wang SP, Foy HM. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. J Infect Dis 1992;166:646-9.
6. 6. Mordhorst CH, Wang SP, Grayston JT. Epidemic "ornithosis" and TWAR infection, Denmark 1976-85. In: Oriel D, Ridgway G, Schachter J, et al., eds Chlamydial infections. Cambridge, UK: Cambridge University Press, 1986:325-8.
7. 7. Kleemola M, Saikku P, Visakorpi R, Wang SP, Grayston JT. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. J Infect Dis 1988;157:230-6.
8. 8. Pether JVS, Wang SP, Grayston JT. Chlamydia pneumoniae, strain TWAR, as the cause of an outbreak in a boys' school previously called psittacosis. Epidemiol Infect 1989;103:395-400.
9. 9. Mordhorst CH, Wang SP, Myhra W, Grayston JT. Chlamydia pneumoniae, strain TWAR, infections in Denmark 1975-1987. In: Bowie WR, Caldwell HD, Jones RP, et al., eds. Chlamydial infections. Cambridge, UK: Cambridge University Press, 1990:418-21.
10. 10. Smadel JE. Atypical pneumonia and psittacosis. J Clin Invest 1943;22:57-65.
11. 11. Chi EY, Kuo CC, Grayston JT. Unique ultrastructure in the elementary body of Chlamydia sp. strain TWAR. J Bacteriol 1987;169:3757-63.
12. 12. Kuo CC, Chi EY, Grayston JT. Ultrastructural study of entry of Chlamydia strain TWAR into HeLa Cells. Infect Immun 1988;56:1668-72.
13. 13. Cox RL, Kuo CC, Grayston JT, Campbell LA. Deoxyribonucleic acid relatedness of Chlamydia sp. strain TWAR to Chlamydia trachomatis and Chlamydia psittaci. Int J Syst Bacteriol 1988;38:265-8.
14. 14. Grayston JT, Kuo CC, Campbell LA, Wang SP. Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int J Syst Bacteriol 1989;39:88-90.
15. 15. Gaydos CA, Quinn TC, Bobo LD, Eiden JJ. Similarity of Chlamydia pneumoniae strains in the variable domain IV region of the major outer membrane protein gene. Infect Immun 1992;60:5319-23.
16. 16. Molestina RE, Dean D, Miller RD, Ramirez JA, Summersgill JT. Characterization of a strain of C. pneumoniae isolated from a coronary atheroma by analysis of the ompl gene and biological activity in human endothelial cells. Infect Immun 1998;66:1370-6.
17. 17. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997;176:292-5.
18. 18. Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaei. J Infect Dis 1985;151:832-9.
19. 19. Aldous MB, Wang SP, Foy HM, Grayston JT. Chlamydia pneumoniae, strain TWAR, infection in Seattle children and their families, 1965-1979. In: Bowie WR, Caldwell HD, Jones RP, et al., eds. Chlamydial infections. Cambridge, UK: Cambridge University Press, 1990:437-40.
20. 20. Patnode D, Wang SP, Grayston JT. Persistence of Chlamydia pneumoniae, strain TWAR micro-immunofluorescent antibody. In: Bowie WR, Caldwell HD, Jones RP, et al., eds. Chlamydial infections, Cambridge, UK: Cambridge University Press, 1990:406-9.
21. 21. Wang SP, Grayston JT. Population prevalence antibody to Chlamydia pneumoniae, strain TWAR. In: Bowie WR, Caldwell HD, Jones RP, et al., eds. Chlamydial infections. Cambridge, UK: Cambridge University Press, 1990:402-5.
22. 22. Wang SP, Grayston JT. Chlamydia pneumoniae (TWAR) microimmunofluorescence antibody studies 1998 update. In: Stephens RS, Byrne BI, Christiansen G, et al., eds. Chlamydial infections. Berkeley, CA: University of California, 1998:155-8.
23. 23. Ekman MR, Grayston JT, Visakorpi R, Kleemola M, Kuo CC, Saikku P. An epidemic of infections due to Chlamydia pneumoniae in military conscripts. Clin Infect Dis 1993;17:420-5.
24. 24. Mordhorst CH, Wang SP, Grayston JT. Transmission of Chlamydia pneumoniae (TWAR). In: Orfila J, Byrne GL, Cherneskey MA, et al., eds. Chlamydial infections. Bologna, Italy: Societa Editrice Esculapio, 1994: 488-91.
25. 25. Malinverni R, Kuo CC, Campbell LA, Grayston JT. Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone. J Infect Dis 1995;172:593-4.
26. 26. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999;354:630-5.
27. 27. Schachter J, Dawson CR. Human chlamydial Infections. Littleton, MA: PSG Publishing, 1978:39-41.
28. 28. Wright SW, Edwards KM, Decker MD, Grayston JT, Wang SP. Prevalence of positive serology for acute Chlamydia pneumoniae infection in emergency department patients with persistent cough. Acad Emerg Med 1997;4:179-83.
29. 29. Schachter J, Dawson CR. Human chlamydial Infections. Littleton, MA: PSG Publishing, 1978:175-7.
30. 30. Beatty W, Morrison R, Byrne G. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994;58:686-99.
31. 31. Grayston JT, Mordhorst CH, Bruu AL, Vene S, Wang SP. Countrywide epidemics of Chlamydia pneumoniae, strain TWAR, in Scandinavia, 1981-1983. J Infect Dis 1989;159:1111-4.
32. 32. Bruu AL, Haukenes G, Aasen S, et al. Chlamydia pneumoniae infections in Norway 1981-87 earlier diagnosed as ornithosis. Scand J Infect Dis 1991;23:299-304.
33. 33. Sutton GC, Driscoll JF, Gunner KM, Tobin JR Jr. Exploratory mediastinotomy in primary myocardial disease. Prog Cardiovasc Dis 1964;7:83-97.
34. 34. Sutton GC, Morrisey RA, Tobin JR Jr, Anderson TO. Pericardial and myocardial disease associated with serological evidence of infection by agents of the psittacosis-lymphogranuloma venereum group (Chlamydiaceae). Circulation 1967;36:830-8.
35. 35. Grayston JT, Mordhorst CH, Wang SP. Childhood myocarditis associated with Chlamydia trachomatis infection. JAMA 1981;246:2823-7.
36. 36. Ringel RE, Givner LB, Brenner JI, et al. Myocarditis as a complication of infantile Chlamydia trachomatis pneumonitis. Clin Pediatr 1983;22:631-3.
37. 37. Jones RB, Priest JB, Kuo CC. Subacute chlamydial endocarditis. JAMA 1982;247:655-8.
38. 38. Marrie TJ, Harczy M, Mann OE, et al. Culture-negative endocarditis probably due to Chlamydia pneumoniae. J Infect Dis 1990;161:127-9.
39. 39. Odeh M, Oliven A. Chlamydial infections of the heart. Eur J Clin Microbiol Infect Dis 1992;11:885-93.
40. 40. Grayston JT, Wang SP, Yeh LJ, Kuo CC. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985;7:717-25.
41. 41. Grayston JT, Gale JL, Yeh LJ, Yang CY. Pathogenesis and immunology of trachoma. Trans Assoc Am Phys 1972;85:203-11.
42. 42. Grayston JT, Wang SP. New knowledge of chlamydiae and the diseases they cause. J Infect Dis 1975;132:87-105.
43. 43. Gale JL, Wang SP, Grayston JT. Chronic trachoma in two Taiwan monkeys ten years after infection. In: Nichols RL, ed. Trachoma and related disorders caused by Chlamydia agents. Amsterdam: Excerpta Medica, 1971: 489-93.
44. 44. Taylor HR, Johnson SL, Prendergast RA, Schachter J, Dawson CR, Silverstein AM. An animal model of trachoma II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci 1982;23:507-15.
45. 45. Patton DL, Kuo CC, Wang SP, Halbert SA. Distal tubal obstruction induced by repeated Chlamydia trachomatis salpingeal infections in the pig-tailed macaques. J Infect Dis 1987;155:1292-9.
46. 46. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
47. 47. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae in atherectomy tissue from patients with symptomatic coronary artery disease. In: Orfila J, Byrne GL, Cherneskey MA, et al., eds. Chlamydial infections. Bologna, Italy: Societa Editrice Esculapio, 1994: 212-5.
48. 48. Maass M, Gieffers J, Krause E, Engel PM, Bartels C, Solbach W. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. Med Microbiol Immunol 1998;187: 103-6.
49. 49. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-9.
50. 50. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997;35:48-52.
51. 51. Laitinen K, Laurila A, Pyhälä L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aorta of rabbits. Infect Immun 1997;65:4832-5.
52. 52. Mühlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97: 633-6.
53. 53. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein (Apo E)-deficient mice. J Infect Dis 1999;180:238-41.
54. 54. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to C. pneumoniae. J Clin Invest 1999;103:747-53.
55. 55. Fong IW. The value of animal models for C. pneumoniae related atherosclerosis. Am Heart J 1999;138:S512-3.
56. 56. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol 1998;148:937-48.
57. 57. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340: 115-26.
58. 58. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, Saikku P, Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb Pathog 1996;21:407-11.
59. 59. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression. A potential link to accelerated arteriosclerosis. Circulation 1999;100:1369-73.
60. 60. Molestina RE, Miller RD, Ramirez JA, Summersgill JT. Infection of human endothelial cells with C. pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect Immun 1999;67:1323-30.
61. 61. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 1998;177:1322-5.
62. 62. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2910-3.
63. 63. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998;177:725-9.
64. 64. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydia heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 1998;98: 300-7.
65. 65. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999;283:1335-9.
66. 66. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15 to 35 years old). Proc Natl Acad Sci USA 1995;92:6911-4.
67. 67. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need far future research. Circulation 1997;96:4095-103.
68. 68. Grayston JT, Jackson LA, Kennedy WJ, Kronmal RA. Secondary prevention trials for coronary artery disease with antibiotic treatment Chlamydia pneumoniae - design issues. Am Heart J 1999;138:S545-47.
69. 69. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999;281: 427-31.
70. 70. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 1999;5: 281-4.
71. 71. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
72. 72. Gurfinkel E, Bozovich G. Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non Q-wave coronary syndromes. Eur Heart J 1999;20:121-7.
73. 73. Anderson JL, Mühlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serologic evidence for Chlamydia pneumoniae infection. Circulation 1999;99:1540-7.
74. 74. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of C. pneumoniae in cardiovascular atheroma. Evaluation of the innocent bystander hypothesis. Am J Pathol 1997;150:1785-90.